Keynote Speaker: João Pedro de Magalhães

Institute of Ageing and Chronic Disease, University of Liverpool 

Emerging opportunities in the business of longevity science

Professor João Pedro de Magalhães graduated in Microbiology in 1999 from the Escola Superior de Biotecnologia in his hometown of Porto, Portugal, and in 2004 obtained a PhD in Biological Sciences from the University of Namur in Belgium. Following further training in genetics at Harvard Medical School (Boston, USA), in 2008 Prof de Magalhaes joined the University of Liverpool in the UK and established the Integrative Genomics of Ageing group. His research on genetics, ageing and longevity has been widely featured in scientific magazines (Science, Nature, Scientific American, New Scientist, etc.), and he has published over 100 scientific papers. Prof de Magalhaes is a world-leader in big data and computational analyses, including genomics and machine learning, in ageing, longevity and age-related diseases. In addition, he has a longterm interest in technological trends and their future impact on society. His work on predicting how technology will shape the human condition has been published in magazines such as Futures and The Futurist, and in newspapers like The Independent. Prof de Magalhaes has given over 100 invited talks in international conferences, including three TEDx talks, and in many academic institutions and companies (e.g., Google’s Calico and Allianz). He also makes regular media appearances (BBC, CNN, the Washington Post, the Financial Times and many others). Prof de Magalhaes is an advisor/consultant for various organizations, including nonprofit foundations and charities, universities, investment funds and biotech companies. He is Chief Scientific Officer of Centaura, an ambitious biotech company in Switzerland focused on healthy ageing, and founded his own his company Magellan Science Ltd.

Internal Speaker: Svitlana Surodina

ARK Entrepreneur in Residence

Department of Informatics, Faculty of Natural & Mathematical Sciences

Caloric restriction mimetics: commercialisation pathways of longevity innovation

Svitlana Surodina is the Entrepreneur in Residence at ARK where she supports commercialisation programmes and conducts research on technological ecosystems for investments in longevity innovation. Svitlana is also the CEO of Skein Group which includes the AI technology innovation company Skein and business accelerator Health-Tech space. She is a member of Open Life Data working group at the UK All-Parliamentary Group for Longevity; holds the degree of Master of Business Administration from the University of Oxford and published academic research on the topics of AI for personal data collection, digital health and data system engineering. Her research at King's is based in the Department of Informatics.

 

Ageing Research at King's (ARK) is a cross-faculty multidisciplinary consortium of investigators which brings together scholarship and research in ageing in several complementary areas. ARK represents King’s world class excellence for research on the biology of ageing, from the basic mechanisms in biogerontology and clinical translation to social impact of ageing and technology transfer. The primary purpose of ARK is to enhance multidisciplinary research collaborations within King’s to better understand the mechanisms of ageing, improving health-span and longevity leading to innovation and entrepreneurship. As ageing consists of complex systems at the level of biology, psychology, society and public policy, in order to understand the processes of ageing and the nature of old age itself, it is important to bring together research and innovation from a number of key disciplines. ARK is uniquely positioned to address the challenges of an ageing world, and to provide answers at multiple levels, from cellular mechanisms and therapeutics to health tech innovations and social sciences, facilitated through an academic-industry hub at King's and ARK global partners.